KKR Real Estate Finance Trust Inc.

KREF reported a GAAP loss of $122 million, or negative $1.95 per share, for Q2 2026. Distributable loss was $36 million, or negative $0.58 per share, while distributable earnings before realized losses were $6 million, or $0.10 per share. Book value was $10.24 per share at June 30, 2026, and the company said book value declined 13.7% in the quarter. The company paid a $0.10 cash dividend for the quarter. On guidance, management said it continues to expect $0.40 per year of dividend to be covered by annual distributable earnings before realized losses, expects earnings to trough later this year and remain in that area over the next several quarters, and still expects more than $2 billion of repayments in 2026.

Matt Salem framed the quarter as a meaningful step in KREF’s portfolio transition and emphasized that the company is trying to move legacy assets through monetization, reserves, modifications, note sales and REO execution. He said the most significant book value impact is now behind the company and that the portfolio should become more stable as resolutions progress. He also addressed the strategic review, saying KKR has not proposed a transaction and that he would not comment further while the independent committee does its work.

Kendra Decious did not speak in the prepared remarks, so the financial commentary came primarily from Jack Switala and management. The call highlighted over $700 million of liquidity at quarter end, including $83 million of cash and $350 million of undrawn corporate revolver capacity, plus $7 billion of total financing availability and 79% non-mark-to-market financing. Management also cited a debt-to-equity ratio of 2.6x and total leverage of 4.3x, saying leverage should naturally move back toward the 3.5x to 4.0x target range as repayments continue. On capital allocation, KREF repurchased $38 million of common stock at a weighted average price of $6.63 per share, generating about $0.32 per share of book value accretion, and bought back another $10 million after quarter-end at $7.24 per share.

Analysts focused on whether book value had now stabilized, what changed in the reserve review versus prior quarters, and how much further downside might remain. Salem said the quarter reflected a discovery process as real-time market feedback came in on clearing values, especially for illiquid office assets, and said the most significant book-value impact is likely behind them, though small adjustments could still occur as resolutions finish. Questions also centered on capital allocation during the strategic review, and management said share repurchases are not necessarily precluded but will be discussed with the committee. Analysts asked for more detail on watch-list sales and Life Science assets; management said it is using the full toolkit—modifications, short sales, note sales and REO—while noting that Boston Life Science is fully reserved and that the broader Life Science market is showing early green shoots, particularly on the West Coast.